Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PSTV
stocks logo

PSTV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.62M
+14.66%
-0.035
-92.86%
1.57M
+48.19%
-0.040
-92.94%
1.69M
+21.37%
-0.040
+515.38%
Estimates Revision
The market is revising Upward the revenue expectations for Plus Therapeutics, Inc. (PSTV) for FY2025, with the revenue forecasts being adjusted by 6.09% over the past three months. During the same period, the stock price has changed by 33.29%.
Revenue Estimates for FY2025
Revise Upward
up Image
+6.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-6.25%
In Past 3 Month
Stock Price
Go Up
up Image
+33.29%
In Past 3 Month
Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 7.75 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 7.75 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.655
sliders
Low
2.00
Averages
7.75
High
21.00
Current: 0.655
sliders
Low
2.00
Averages
7.75
High
21.00
H.C. Wainwright
Buy
downgrade
$3 -> $2
2025-11-03
Reason
H.C. Wainwright
Price Target
$3 -> $2
2025-11-03
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Plus Therapeutics to $2 from $3 and keeps a Buy rating on the shares. The firm cites dilution associated with the equity raise for the target drop.
D. Boral Capital
Jason Kolbert
Hold
to
Buy
upgrade
$5
2025-09-03
Reason
D. Boral Capital
Jason Kolbert
Price Target
$5
2025-09-03
upgrade
Hold
to
Buy
Reason
D. Boral Capital analyst Jason Kolbert upgraded Plus Therapeutics to Buy from Hold with a $5 price target. The firm, which previously had lowered its rating in May on concerns that the company was likely to execute a reverse split, says it seems those concerns "may have faded" for the moment and also cites the progress the company has been making on the diagnostics side. With catalysts such as a diagnostics launch, the firm sees the stock being back up over the "critical $1.00 mark," the analyst added.
Maxim
Buy
downgrade
$4 -> $3
2025-08-18
Reason
Maxim
Price Target
$4 -> $3
2025-08-18
downgrade
Buy
Reason
Maxim lowered the firm's price target on Plus Therapeutics to $3 from $4 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company's equity dilution but also notes that its restructuring is a positive, transforming a highly dilutive equity financing into a less dilutive financing that can be thought of as 35M prefunded warrants plus $15M in debt, the analyst tells investors in a research note.
H.C. Wainwright
Sean Lee
Buy
downgrade
$3
2025-06-27
Reason
H.C. Wainwright
Sean Lee
Price Target
$3
2025-06-27
downgrade
Buy
Reason
H.C. Wainwright analyst Sean Lee lowered the firm's price target on Plus Therapeutics to $3 from $5.50 and keeps a Buy rating on the shares. The firm cites the restructured number of outstanding shares and warrants associated with the March equity offering for the target cut.
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$19 → $20
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$19 → $20
2025-04-21
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-03-28
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-03-28
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Plus Therapeutics Inc (PSTV.O) is -4.52, compared to its 5-year average forward P/E of -1.23. For a more detailed relative valuation and DCF analysis to assess Plus Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.23
Current PE
-4.52
Overvalued PE
-0.40
Undervalued PE
-2.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.29
Undervalued EV/EBITDA
-2.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.14
Current PS
0.00
Overvalued PS
9.59
Undervalued PS
-3.31
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PSTV News & Events

Events Timeline

(ET)
2025-12-04
07:40:00
Plus Therapeutics Announces Three Positive Clinical Data Updates at Neuro-Oncology Annual Meeting
select
2025-11-24 (ET)
2025-11-24
07:40:08
Plus Therapeutics concludes FDA meeting regarding REYOBIQ development strategy.
select
2025-11-20 (ET)
2025-11-20
07:33:17
Plus Therapeutics' test gains national coverage agreement with Humana
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-24Newsfilter
Plus Therapeutics Advances REYOBIQ Clinical Plans Following FDA Type B Meeting
  • FDA Meeting Outcome: Plus Therapeutics held a Type B meeting with the FDA on November 7 to discuss clinical development plans for REYOBIQ targeting leptomeningeal metastases. This constructive meeting reflects positive interactions with the FDA, aiding in the design and implementation of clinical trials.
  • Clinical Trial Update: The company plans to provide updates and guidance on next steps in early 2026, implementing specific amendments to the LM trial based on FDA recommendations. These changes aim to accelerate the overall clinical development timeline in alignment with regulatory expectations.
  • Urgent Treatment Need: Leptomeningeal metastases are a severe complication affecting approximately 5% of metastatic cancer patients, with median survival typically ranging from 2 to 6 months, highlighting the urgent need for novel therapies. REYOBIQ aims to enhance treatment outcomes for CNS cancer patients.
  • Funding Support: The clinical trials for REYOBIQ are backed by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas and a $3 million grant from the U.S. Department of Defense. This funding underscores the company's potential in advancing cancer treatment solutions.
[object Object]
Preview
6.0
11-21Benzinga
Palo Alto Set to Surge by 30%? Check Out 10 Leading Analyst Predictions for Friday

  • Analyst Downgrades: Baird downgraded Bath & Body Works Inc from Outperform to Neutral, lowering the price target from $33 to $19, while also cutting Jacobs Solutions Inc's target from $161 to $146 and downgrading it to Neutral.

  • Analyst Upgrades: Goldman Sachs upgraded Helmerich and Payne Inc from Sell to Neutral, raising its price target from $20 to $28, and B of A Securities maintained a Buy rating for Block Inc, increasing its target from $86 to $88.

  • Price Target Increases: Needham raised the price target for Kulicke And Soffa Industries Inc from $40 to $46, and BTIG increased Walmart Inc's target from $120 to $125, both maintaining Buy ratings.

  • Mixed Ratings: Ascendiant Capital cut Plus Therapeutics Inc's target from $21 to $19 while keeping a Buy rating, and Morgan Stanley reduced Brightview Holdings Inc's target from $16 to $12, maintaining an Equal-Weight rating.

[object Object]
Preview
6.0
11-21Benzinga
Ascendiant Capital Reaffirms Buy Rating on Plus Therapeutics, Adjusts Price Target to $19

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for market success.

  • Market Winning Tools: The platform provides tools and resources that traders use daily to improve their chances of winning in the markets.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Plus Therapeutics Inc (PSTV) stock price today?

The current price of PSTV is 0.655 USD — it has increased 9.72 % in the last trading day.

arrow icon

What is Plus Therapeutics Inc (PSTV)'s business?

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

arrow icon

What is the price predicton of PSTV Stock?

Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 7.75 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Plus Therapeutics Inc (PSTV)'s revenue for the last quarter?

Plus Therapeutics Inc revenue for the last quarter amounts to 1.40M USD, decreased -4.05 % YoY.

arrow icon

What is Plus Therapeutics Inc (PSTV)'s earnings per share (EPS) for the last quarter?

Plus Therapeutics Inc. EPS for the last quarter amounts to -0.04 USD, decreased -89.19 % YoY.

arrow icon

What changes have occurred in the market's expectations for Plus Therapeutics Inc (PSTV)'s fundamentals?

The market is revising Upward the revenue expectations for Plus Therapeutics, Inc. (PSTV) for FY2025, with the revenue forecasts being adjusted by 6.09% over the past three months. During the same period, the stock price has changed by 33.29%.
arrow icon

How many employees does Plus Therapeutics Inc (PSTV). have?

Plus Therapeutics Inc (PSTV) has 21 emplpoyees as of December 05 2025.

arrow icon

What is Plus Therapeutics Inc (PSTV) market cap?

Today PSTV has the market capitalization of 90.02M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free